PODD logo

Insulet Corporation

PODD · What the business does, what can go wrong, and how options sellers approach it

What it does

Insulet makes the Omnipod, a wearable insulin delivery system for people with diabetes. Instead of a traditional insulin pump with tubing, the Omnipod uses a small disposable pod that sticks to the skin and delivers insulin through a tiny cannula. A separate controller or a compatible smartphone app manages dosing.

The system can connect with continuous glucose monitors and adjust insulin delivery automatically. It is used mainly by people with type 1 diabetes, and increasingly by people with type 2 diabetes who use insulin.

How it makes money

Most revenue comes from the pods, which are replaced every few days. That creates a recurring, consumable-style model: customers keep buying pods as long as they stay on therapy.

Pods are sold through pharmacies and other channels, in the United States and abroad. Insurance coverage shapes patient access.

Why investors own it

  • Recurring demand: Diabetes is a chronic condition, and patients who like their system tend to stay with it.
  • Growth runway: Many insulin users still rely on injections, so there is room for more adoption.
  • Differentiation: The tubeless design is a distinct feature in a market with several competitors.

What can go wrong

  • Competition: Larger medical device companies and newer entrants offer rival pumps and automated insulin systems.
  • Safety and quality: Product recalls, regulatory actions, manufacturing problems or component shortages can hurt trust and sales.
  • Reimbursement: Changes in insurance or government coverage can affect patient access and pricing.
  • Partner dependence: The system relies on compatibility with glucose monitors made by other companies.
  • Valuation sensitivity: Growth-oriented stocks can fall sharply when results or guidance disappoint.

What to watch

  • New patient starts and customer growth
  • U.S. and international revenue growth
  • Gross margin trends
  • Pharmacy channel adoption
  • Progress with type 2 diabetes use
  • Regulatory approvals and product updates
  • Competitor launches and glucose monitor partnerships

Options income angle

Options on PODD are typically reasonably liquid, though spreads can widen on less active strikes.

Implied volatility tends to rise ahead of earnings, regulatory news, competitor announcements and shifts in sentiment toward medical technology stocks.

One caution for premium sellers: a sharp move after earnings or a product issue can happen quickly, and premium collected may not offset a large drop.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 18, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Insulet reported revenue of $2,708.1 million for 2025, up 30.7%, with nearly all of it coming from the Omnipod insulin delivery platform. Growth came mainly from more customers, especially in the U.S. and in newly launched international markets. The risk section points to concentration in one product, a China-based contract manufacturer, and possible U.S. medical device tariffs.

How the business did

  • Revenue rose to $2,708.1 million from $2,071.6 million. U.S. Omnipod revenue was $1,919.8 million, up 27.2%, and International was $754.3 million, up 44.1%. Constant currency growth, which holds exchange rates at prior-year levels, was 29.5% in total. Higher sales volume drove most of it.
  • Drug Delivery, which is mostly pods sold to Amgen, fell 12.3% to $34.1 million.
  • Gross margin was 71.6%, compared with 69.8%. Management credited manufacturing and supply chain efficiencies, a higher average selling price and higher volume. Net income was $247.1 million, compared with $418.3 million. The prior year included an income tax benefit and the current year included a $123.9 million loss on buying back convertible notes.
  • Adjusted EBITDA, a non-GAAP measure that strips out items such as interest, taxes, stock compensation and one-time events, was $645.5 million, compared with $457.2 million. Operating cash flow was $569.3 million and free cash flow was $377.7 million.
  • A jury awarded the company $452 million in a trade secret case against EOFlow, and the court later reduced the award to $59.4 million. The company has not recorded it as income because EOFlow has appealed and its ability to pay is uncertain.

Risks specific to this company

  • Insulet expects to keep deriving nearly all its revenue from Omnipod, so any setback in selling it or keeping customers would hit the whole business.
  • Products come from three locations, including lines at a facility in China run by a third-party contract manufacturer. Substantially all U.S. inventory sits at a single location in Massachusetts, and European inventory is mainly at a single location in the Netherlands.
  • Tariffs are a flagged concern. A U.S. Section 232 national security investigation covers medical devices such as insulin pumps and could override the current tariff exemption. Management said tariffs would then have a material impact on results in future years.
  • Payors such as insurers can generally end Omnipod coverage contracts without cause. International sales were 28% of revenues in 2025, and foreign reimbursement is uncertain.
  • Omnipod 5 depends on integration agreements with Dexcom and Abbott sensors. The Glooko data partnership expires in December 2026. The Amgen agreement behind most Drug Delivery revenue expires in December 2028.
  • The chief executive and chief financial officer both changed in 2025, and the filing notes the risk of integrating new leaders. Competitors named include Tandem, Beta Bionics and Medtronic's diabetes unit, and the filing also points to GLP-1 drugs as a possible threat.

What management is watching

  • Management expects strong U.S. revenue growth in 2026 from recurring pod sales and Omnipod 5 volume. It expects higher International revenue from new customers and higher prices as users convert to Omnipod 5.
  • Capital spending is expected to rise. The company is building a plant in Costa Rica and adding equipment in Malaysia, funded by existing cash and financing.
  • Net interest expense is expected to increase to $40 million or more because of lower interest income.
  • The company plans to use $300 million of existing cash to repurchase shares in the first quarter of 2026, after the board approved an additional $350 million in repurchases.
  • Pipeline work includes Omnipod 6, a fully closed loop system for type 2 diabetes, and integration with Abbott's FreeStyle Libre 3 Plus. Management points investors to constant currency revenue growth, Adjusted EBITDA and free cash flow.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Insulet's revenue for the three months ended September 30, 2026 rose 19.2% to $842.0 million, and net income was $141.1 million, compared with $87.6 million a year earlier. Gross margin widened to 75.1% from 72.2%. Cash generation for the nine months was weaker: free cash flow (cash from operations minus capital spending) was $211.7 million, compared with $329.5 million.

How the business did

  • Revenue: U.S. Omnipod revenue was $570.4 million, up 14.7%. International was $266.2 million, up 31.7% (33.0% in constant currency, which removes exchange-rate effects). Drug Delivery, which is mostly Pods sold to Amgen, fell to $5.5 million from $7.1 million on lower order volumes. Nine-month revenue was $2,405.4 million, up 25.0%. Management attributed growth mainly to higher volume from a growing customer base.
  • Margins and costs: The 280 basis point gross margin gain (a basis point is one hundredth of a percentage point) came mainly from manufacturing efficiencies. A smaller 90 basis point piece came from lowering a warranty estimate because fewer Pods needed replacing than expected. R&D expenses were $91.6 million and selling, general and administrative expenses were $350.7 million. Adjusted EBITDA, a non-GAAP profit measure that excludes certain items, was $233.7 million, compared with $160.0 million.
  • Unusual items: Two voluntary medical device corrections, in March and May, addressed manufacturing issues that tore the cannula (the small tube that delivers insulin) in certain products. The net charge for the nine months was $38.5 million. Total costs are estimated at approximately $50 million, most of it in 2026. The effective tax rate was 20.4%, compared with 28.7%.
  • Cash and capital return: Operating cash flow for the nine months was $325.7 million, compared with $386.0 million, with a $177.3 million working capital outflow driven by higher receivables and inventories. Capital expenditures were $113.9 million, compared with $56.5 million. The company repurchased $300.0 million of common stock and ended September with cash and cash equivalents of $584.4 million.

What management is watching

  • Spending and financing: Management expects 2026 capital expenditures to rise compared with 2025, supporting manufacturing expansion including a new plant in Costa Rica. It expects full-year 2026 net interest expense of approximately $40 million, mainly because interest income is lower. In October 2026 the Board authorized a $1 billion repurchase program through December 31, 2028, with approximately $400 million expected toward repurchases in 2026, funded with existing cash.
  • Products and markets: Omnipod 6 is in development, and enrollment is complete for the type 1 cohort of the STRIVE 2 study. Enrollment is also complete in the EVOLVE pivotal study for a fully closed-loop system for type 2 diabetes, which is intended to support a planned 510(k) submission (the FDA filing for device clearance) in 2027. Omnipod 5 launched in Spain in July 2026.
  • Tariffs: Management does not expect tariffs to significantly affect 2026 gross margin. It says that removing the exemption for certain medical devices would have a material impact on gross margin and results in future periods.
  • Measures to watch: The filing points to constant currency revenue growth, Adjusted EBITDA and free cash flow. Constant currency revenue growth is also one of the metrics that determines management incentive compensation.

Follow PODD in Kortex

The Kortex app shows PODD's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.